We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+9.18%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.17B
AUM Growth
-$203M
Cap. Flow
-$271M
Cap. Flow %
-23.1%
Top 10 Hldgs %
53.52%
Holding
83
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
TEVA icon
Teva Pharmaceuticals
TEVA
+$20M
2
NTRA icon
Natera
NTRA
+$15.8M
3
COR icon
Cencora
COR
+$15.4M
4
MASI
Masimo
MASI
+$15.1M
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$12.9M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$61.6M
2
ABBV icon
AbbVie
ABBV
+$54.1M
3
ELV icon
Elevance Health
ELV
+$38.4M
4
ARGX icon
argenx
ARGX
+$35.8M
5
UHS icon
Universal Health Services
UHS
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 94.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AKRO
26
DELISTED
Akero Therapeutics
AKRO
$14.2M 1.21%
+266,167
New +$12.1M
HOLX
27
DELISTED
Hologic
HOLX
$13.8M 1.18%
+211,986
New +$12.7M
IRTC icon
28
iRhythm Holdings
IRTC
$3.91B
$13.6M 1.16%
+88,157
New +$11.4M
ARQT icon
29
Arcutis Biotherapeutics
ARQT
$3.5B
$12.9M 1.1%
+923,375
New +$12.9M
ICLR icon
30
Icon
ICLR
$12.8B
$12.8M 1.09%
88,181
+47,143
+115% +$6.69M
UNH icon
31
UnitedHealth
UNH
$383B
$10.8M 0.92%
34,623
-1,281
-4% -$490K
SPY icon
32
State Street SPDR S&P 500 ETF Trust
SPY
$784B
$10.6M 0.9%
+17,129
New +$9.79M
UTHR icon
33
United Therapeutics
UTHR
$26.2B
$10.5M 0.89%
+36,391
New +$10.9M
BMRN icon
34
BioMarin Pharmaceuticals
BMRN
$11.7B
$9.8M 0.83%
+178,319
New +$10.5M
MRUS
35
DELISTED
Merus
MRUS
$9.67M 0.82%
+183,882
New +$8.64M
VRNA
36
DELISTED
Verona Pharma
VRNA
$7.61M 0.65%
+80,416
New +$5.95M
ABBV icon
37
AbbVie
ABBV
$455B
$7.57M 0.64%
40,782
-290,959
-88% -$54.1M
BPMC
38
DELISTED
Blueprint Medicines
BPMC
$6.21M 0.53%
48,444
+1,991
+4% +$207K
NEO icon
39
NeoGenomics
NEO
$2.04B
$5.63M 0.48%
770,038
+184,657
+32% +$1.49M
CMPS
40
Compass Pathways
CMPS
$1.56B
$4.98M 0.42%
1,779,259
+1,327,992
+294% +$5M
AMLX icon
41
Amylyx Pharmaceuticals
AMLX
$2.31B
$4.69M 0.4%
732,256
-101,879
-12% -$496K
CNTA
42
DELISTED
Centessa Pharmaceuticals
CNTA
$4.53M 0.39%
344,972
-225,574
-40% -$2.86M
ARGX icon
43
argenx
ARGX
$54.6B
$3.99M 0.34%
7,237
-61,762
-90% -$35.8M
PRAX icon
44
Praxis Precision Medicines
PRAX
$8.58B
$3.56M 0.3%
84,713
-76,153
-47% -$2.9M
INBX icon
45
Inhibrx
INBX
$1.24B
$3.49M 0.3%
244,261
-195,022
-44% -$2.52M
IOBT
46
DELISTED
IO Biotech
IOBT
$2.74M 0.23%
1,972,073
-369,034
-16% -$423K
QURE icon
47
uniQure
QURE
$2.93B
$2.43M 0.21%
174,331
-425,636
-71% -$5.73M
RZLT icon
48
Rezolute
RZLT
$470M
$1.94M 0.16%
+434,134
New +$1.61M
CRBU icon
49
Caribou Biosciences
CRBU
$150M
$1.71M 0.15%
1,358,831
-1,147,604
-46% -$1.13M
IRON icon
50
Disc Medicine
IRON
$3.03B
$1.63M 0.14%
+30,799
New +$1.45M
1
2
3 4

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return
MIA
MMBG Investment Advisors Miami, Florida $1.09B AUM 30.96% 1-Year Est. Return
AC
AWM Capital Phoenix, Arizona $1.1B AUM 15.03% 1-Year Est. Return

PFM Health Sciences's Q2 2025 Portfolio in Review

As of Q2 2025, PFM Health Sciences held 83 positions worth $1.17B, down 15% from $1.38B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

PFM Health Sciences withdrew a net $271M in Q2 2025, closing 26 positions and reducing 24 holdings. Its most notable exit was Vertex Pharmaceuticals, an estimated $61.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 92% a quarter earlier.

Against the trend, PFM Health Sciences opened a new position in Teva Pharmaceuticals worth $20.8M.

  • PFM Health Sciences's largest Q2 2025 buy was Teva Pharmaceuticals: 1,238,846 shares worth $20.8M.
  • PFM Health Sciences added most to Humana in Q2 2025, an estimated $11.5M increase.
  • PFM Health Sciences's biggest Q2 2025 reduction was AbbVie, cutting an estimated $54.1M.
  • PFM Health Sciences fully exited Vertex Pharmaceuticals in Q2 2025, selling an estimated $61.6M.
  • PFM Health Sciences's ten largest holdings make up 54% of its $1.17B portfolio in Q2 2025.
  • PFM Health Sciences opened 18 new positions and closed 26 in Q2 2025.
  • PFM Health Sciences's portfolio value fell 15% quarter-over-quarter to $1.17B.

Based on PFM Health Sciences's 13F filing for Q2 2025, filed 14 Aug 2025.